Home » Stocks » Biospecifics Technologies

Biospecifics Technologies Corp. (BSTC)

Stock Price: $88.16 USD 27.14 (44.48%)
Updated Oct 19, 2020 10:50 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 647.53M
Revenue (ttm) 34.78M
Net Income (ttm) 18.24M
Shares Out 7.34M
EPS (ttm) 2.48
PE Ratio 35.55
Forward PE 12.14
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $88.16
Previous Close $61.02
Change ($) 27.14
Change (%) 44.48%
Day's Open 88.07
Day's Range 88.05 - 88.25
Day's Volume 452,284
52-Week Range 42.00 - 88.25

More Stats

Market Cap 647.53M
Enterprise Value 548.68M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.34M
Float 5.78M
EPS (basic) 2.50
EPS (diluted) 2.48
FCF / Share 3.71
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.81%
FCF Yield 4.20%
Payout Ratio n/a
Shares Short 232,742
Short Ratio 5.93
Short % of Float 4.03%
Beta 0.72
PE Ratio 35.55
Forward PE 12.14
P/FCF Ratio 23.80
PS Ratio 18.62
PB Ratio 3.46
Revenue 34.78M
Operating Income 21.26M
Net Income 18.24M
Free Cash Flow 27.21M
Net Cash 98.85M
Net Cash / Share 13.46
Gross Margin 109.81%
Operating Margin 61.12%
Profit Margin 52.50%
FCF Margin 78.24%
ROA 11.70%
ROE 15.22%
ROIC 20.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$100.00*
Low
100
Current: $88.16
High
100
Target: 100.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue38.1932.9627.4426.2522.7514.0414.4311.1511.405.66
Revenue Growth15.86%20.11%4.54%15.39%61.98%-2.67%29.47%-2.2%101.29%-
Gross Profit38.1932.9627.4426.2522.7514.0414.4311.1511.405.66
Operating Income28.3123.4017.6817.0314.446.977.915.125.19-2.03
Net Income24.4720.0511.3311.379.624.655.292.986.60-1.51
Shares Outstanding7.327.247.177.066.836.486.356.356.346.26
Earnings Per Share3.332.731.551.561.320.660.760.430.95-0.24
EPS Growth21.98%76.13%-0.64%18.18%100%-13.16%76.74%-54.74%--
Operating Cash Flow22.2917.7313.1616.3510.616.134.540.93-0.69-0.88
Capital Expenditures----------
Free Cash Flow22.2917.7313.1616.3510.616.134.540.93-0.69-0.88
Cash & Equivalents89.2480.8859.3149.0233.4920.7112.598.508.207.83
Total Debt0.24---------
Net Cash / Debt89.0080.8859.3149.0233.4920.7112.598.508.207.83
Assets12710075.0064.7045.7031.0323.2518.3916.2711.52
Liabilities2.162.507.488.410.890.770.920.931.394.82
Book Value12497.5967.5256.2844.8130.2622.3317.4614.876.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biospecifics Technologies Corp.
Country United States
Employees 7
CEO Joseph Truitt

Stock Information

Ticker Symbol BSTC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BSTC
IPO Date November 14, 1991

Description

BioSpecifics Technologies, a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.